Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.38
+$0.96 (+2.38%)
At close: Oct 30, 2026, 3:59 PM ET
$41.66
+$0.28 (+0.68%)
After-hours:
Oct 30, 2026, 7:48 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Cash & Equivalents | 87.97M |
Short-Term Investments | 97.51M |
Long-Term Investments | n/a |
Other Long-Term Assets | 531K |
Receivables | 2.63M |
Inventory | n/a |
Other Current Assets | n/a |
Total Current Assets | 192.55M |
Property-Plant & Equipment | 1.7M |
Goodwill & Intangibles | n/a |
Total Long-Term Assets | 2.23M |
Total Assets | 194.78M |
Account Payables | 5.73M |
Deferred Revenue | n/a |
Short-Term Debt | n/a |
Other Current Liabilities | 3.01M |
Total Current Liabilities | 10.68M |
Long-Term Debt | n/a |
Other Long-Term Liabilities | 360.17M |
Total Long-Term Liabilities | 360.74M |
Total Liabilities | 371.42M |
Total Debt | 1.22M |
Book Value | -176.64M |
Book Value Per Share | -6.44 |
Common Stock | 132K |
Retained Earnings | -181.86M |
Comprehensive Income | 175K |
Shareholders Equity | -176.64M |
Total Investments | 97.51M |
Add to Watchlist
Select watchlists to add or remove COAG